Genix Pharmaceuticals Corporation
GENPF
$0.01
-$0.02-53.00%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 100.00 | 800.00 | 2.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 100.00 | 800.00 | 2.90K |
| Cost of Revenue | -- | -- | 134.10K | 134.40K | 135.40K |
| Gross Profit | -- | -- | -134.00K | -133.50K | -132.30K |
| SG&A Expenses | 83.50K | 89.10K | 111.60K | 118.00K | 125.40K |
| Depreciation & Amortization | 600.00 | 800.00 | 800.00 | 800.00 | 800.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.10K | 89.90K | 246.50K | 253.20K | 261.60K |
| Operating Income | -84.10K | -89.90K | -246.40K | -252.40K | -258.60K |
| Income Before Tax | -202.00K | -239.40K | -60.10K | -59.30K | -86.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.20 | -0.24 | -0.06 | -0.06 | -0.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -202.00K | -239.40K | -60.10K | -59.30K | -86.00K |
| EBIT | -84.10K | -89.90K | -246.40K | -252.40K | -258.60K |
| EBITDA | -67.80K | -89.10K | -245.60K | -251.60K | -257.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 240.17M | 238.17M | 236.90M | 236.90M | 236.90M |
| Average Diluted Shares Outstanding | 240.17M | 238.17M | 236.90M | 236.90M | 236.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |